JP2013511496A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013511496A5 JP2013511496A5 JP2012539355A JP2012539355A JP2013511496A5 JP 2013511496 A5 JP2013511496 A5 JP 2013511496A5 JP 2012539355 A JP2012539355 A JP 2012539355A JP 2012539355 A JP2012539355 A JP 2012539355A JP 2013511496 A5 JP2013511496 A5 JP 2013511496A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- composition according
- carbon atoms
- dosage form
- oral
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 12
- 150000001335 aliphatic alkanes Chemical class 0.000 claims 4
- 125000004432 carbon atom Chemical group C* 0.000 claims 4
- 239000002552 dosage form Substances 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 150000002430 hydrocarbons Chemical group 0.000 claims 3
- OLBCVFGFOZPWHH-UHFFFAOYSA-N propofol Chemical compound CC(C)C1=CC=CC(C(C)C)=C1O OLBCVFGFOZPWHH-UHFFFAOYSA-N 0.000 claims 3
- 229960004134 propofol Drugs 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 2
- 239000000499 gel Substances 0.000 claims 2
- 239000007788 liquid Substances 0.000 claims 2
- 206010002091 Anaesthesia Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 206010028813 Nausea Diseases 0.000 claims 1
- 206010039897 Sedation Diseases 0.000 claims 1
- 239000000443 aerosol Substances 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 230000037005 anaesthesia Effects 0.000 claims 1
- 208000029028 brain injury Diseases 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 239000007922 nasal spray Substances 0.000 claims 1
- 230000008693 nausea Effects 0.000 claims 1
- 230000004112 neuroprotection Effects 0.000 claims 1
- 239000000668 oral spray Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 150000003904 phospholipids Chemical class 0.000 claims 1
- 230000036280 sedation Effects 0.000 claims 1
- 239000007901 soft capsule Substances 0.000 claims 1
- 150000003626 triacylglycerols Chemical class 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09014548A EP2332525A1 (en) | 2009-11-23 | 2009-11-23 | Pharmaceutical composition comprising propofol |
| EP09014548.3 | 2009-11-23 | ||
| PCT/EP2010/067938 WO2011061332A1 (en) | 2009-11-23 | 2010-11-22 | Pharmaceutical composition comprising propofol |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013511496A JP2013511496A (ja) | 2013-04-04 |
| JP2013511496A5 true JP2013511496A5 (enExample) | 2013-12-05 |
| JP5707009B2 JP5707009B2 (ja) | 2015-04-22 |
Family
ID=41694756
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012539355A Active JP5707009B2 (ja) | 2009-11-23 | 2010-11-22 | プロポフォールを含有する医薬組成物 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US8796340B2 (enExample) |
| EP (2) | EP2332525A1 (enExample) |
| JP (1) | JP5707009B2 (enExample) |
| KR (1) | KR20120104262A (enExample) |
| CN (1) | CN102753159B (enExample) |
| AU (1) | AU2010320823B2 (enExample) |
| BR (1) | BR112012012108A2 (enExample) |
| CA (1) | CA2776855C (enExample) |
| ES (1) | ES2450423T3 (enExample) |
| IN (1) | IN2012DN03130A (enExample) |
| MX (1) | MX2012005881A (enExample) |
| WO (1) | WO2011061332A1 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2564502T3 (es) | 2010-03-17 | 2016-03-23 | Novaliq Gmbh | Composición farmacéutica para el tratamiento de la presión intraocular aumentada |
| EP2444063A1 (en) | 2010-10-20 | 2012-04-25 | Novaliq GmbH | Liquid pharmaceutical compositions for the delivery of active ingredients |
| EP2462921A1 (en) | 2010-11-11 | 2012-06-13 | Novaliq GmbH | Liquid pharmaceutical compositions for the treatment of a posterior eye disease |
| EP3192501B1 (en) | 2011-05-25 | 2020-05-13 | Novaliq GmbH | Topical pharmaceutical composition based on semifluorinated alkanes |
| CN103561724B (zh) | 2011-05-25 | 2016-06-29 | 诺瓦利克有限责任公司 | 给药给甲的药物组合物 |
| GB201116271D0 (en) | 2011-09-21 | 2011-11-02 | Univ Cardiff | Dispersion anaesthetic device |
| ES2625538T3 (es) | 2012-01-23 | 2017-07-19 | Novaliq Gmbh | Composiciones de proteínas estabilizadas basadas en alcanos semifluorados |
| MY166228A (en) | 2012-09-12 | 2018-06-22 | Novaliq Gmbh | Compositions comprising mixtures of semifluorinated alkanes |
| ES2682064T3 (es) * | 2012-09-12 | 2018-09-18 | Novaliq Gmbh | Composiciones para el lavado de ojos |
| EP4342537A3 (en) | 2012-09-12 | 2024-07-03 | Novaliq GmbH | Semifluorinated alkane compositions |
| DK3024484T3 (en) | 2013-07-23 | 2018-10-08 | Novaliq Gmbh | STABILIZED ANTIBODY COMPOSITIONS |
| EP2944324A1 (de) * | 2014-05-13 | 2015-11-18 | LTS LOHMANN Therapie-Systeme AG | Verwendung von semifluorierten Alkanen in transdermalen therapeutischen Systemen |
| EP3206683A4 (en) | 2014-10-16 | 2018-06-13 | The Board of Trustees of the Leland Stanford Junior University | Novel methods, compounds, and compositions for anesthesia |
| DE202016008738U1 (de) | 2015-09-30 | 2019-04-09 | Novaliq Gmbh | Semifluorierte Verbindungen und ihre Zusammensetzungen |
| CN113662928A (zh) | 2015-09-30 | 2021-11-19 | 诺瓦利克有限责任公司 | 用于眼部给药的半氟化化合物 |
| PT3442480T (pt) | 2016-06-23 | 2019-12-23 | Novaliq Gmbh | Método de administração tópica |
| KR102614858B1 (ko) | 2016-09-22 | 2023-12-18 | 노바리크 게엠베하 | 안검염 치료에 사용되는 약제학적 조성물 |
| AU2017329983B2 (en) | 2016-09-23 | 2022-05-05 | Novaliq Gmbh | Ophthalmic compositions comprising ciclosporin |
| EP3612228B1 (en) | 2017-04-21 | 2023-08-23 | Dermaliq Therapeutics, Inc. | Iodine compositions |
| WO2018206656A1 (en) | 2017-05-12 | 2018-11-15 | Novaliq Gmbh | Pharmaceutical compositions comprosing semifluorinated alkanes for the treatment of contact lense-related conditions |
| BR112020006072A2 (pt) | 2017-09-27 | 2020-10-06 | Novaliq Gmbh | composições oftalmáticas compreendendo latanoprost para uso no tratamento de doenças oculares |
| CN119909046A (zh) | 2017-10-04 | 2025-05-02 | 诺瓦利克有限责任公司 | 包含f6h8的眼用组合物 |
| EP3758676A1 (en) | 2018-03-02 | 2021-01-06 | Novaliq GmbH | Pharmaceutical compositions comprising nebivolol |
| CN112153970A (zh) | 2018-04-27 | 2020-12-29 | 诺瓦利克有限责任公司 | 用于治疗青光眼的包含他氟前列素的眼用组合物 |
| CA3112504A1 (en) | 2018-09-27 | 2020-04-02 | Novaliq Gmbh | Lipid barrier repair |
| CA3112031A1 (en) | 2018-10-12 | 2020-04-16 | Novaliq Gmbh | Ophthalmic composition for treatment of dry eye disease |
| EP3923907B1 (en) | 2019-02-13 | 2024-09-25 | Novaliq GmbH | Compositions and methods for the treatment of ocular neovascularization |
| BR112022004677A2 (pt) | 2019-09-06 | 2022-05-17 | Novaliq Gmbh | Composição oftálmica para o tratamento de uveíte |
| EP3912622A1 (en) | 2020-05-19 | 2021-11-24 | tesa Labtec GmbH | Oral film for safe administration of api |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5496537A (en) * | 1995-03-23 | 1996-03-05 | Henry; Richard A. | Propofol hydrofluorocarbon propellant formulations |
| DE19536504C2 (de) | 1995-09-29 | 1999-09-23 | H Meinert | Verwendung fluorierter Alkane |
| EP1124416A1 (en) * | 1999-03-15 | 2001-08-22 | John Claude Krusz | Treatment of acute headaches and chronic pain using rapidly-cleared anesthetic drug at sub-anesthetic dosages |
| GB0124071D0 (en) * | 2001-10-08 | 2001-11-28 | Kbig Ltd | Improvement in the administration of high boiling point aneasthetics |
| WO2005067517A2 (en) * | 2004-01-02 | 2005-07-28 | Wisconsin Alumni Research Foundation | Encapsulation of chemical compounds in fluorous-core and fluorous-inner-shell micelles formed from semifluorinated-block or fluorinated-block copolymers |
| DE102004030044A1 (de) | 2004-06-22 | 2006-01-12 | Birken Gmbh | Triterpenhaltiger Oleogelbildner, triterpenhaltiges Oleogel und Verfahren zur Herstellung eines triterpenhaltigen Oleogels |
| JP5569899B2 (ja) * | 2006-11-28 | 2014-08-13 | ウィスコンシン・アラムナイ・リサーチ・ファウンデーション | 揮発性のフッ化麻酔薬を静脈内送達するためのフルオロポリマーベースのエマルション |
| EP2110126B9 (de) | 2008-04-18 | 2012-09-19 | Novaliq GmbH | Inhalative und instillative Verwendung von semifluorierten Alkanen als Wirkstoffträger im intrapulmonalen Bereich |
-
2009
- 2009-11-23 EP EP09014548A patent/EP2332525A1/en not_active Withdrawn
-
2010
- 2010-11-22 JP JP2012539355A patent/JP5707009B2/ja active Active
- 2010-11-22 CA CA2776855A patent/CA2776855C/en active Active
- 2010-11-22 US US13/511,184 patent/US8796340B2/en active Active
- 2010-11-22 BR BR112012012108A patent/BR112012012108A2/pt not_active Application Discontinuation
- 2010-11-22 ES ES10778677.4T patent/ES2450423T3/es active Active
- 2010-11-22 KR KR1020127016348A patent/KR20120104262A/ko not_active Withdrawn
- 2010-11-22 CN CN201080052400.7A patent/CN102753159B/zh active Active
- 2010-11-22 MX MX2012005881A patent/MX2012005881A/es not_active Application Discontinuation
- 2010-11-22 IN IN3130DEN2012 patent/IN2012DN03130A/en unknown
- 2010-11-22 AU AU2010320823A patent/AU2010320823B2/en active Active
- 2010-11-22 WO PCT/EP2010/067938 patent/WO2011061332A1/en not_active Ceased
- 2010-11-22 EP EP10778677.4A patent/EP2503999B1/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013511496A5 (enExample) | ||
| US10639439B2 (en) | Smokeless THC and administration method thereof | |
| ES2894836T3 (es) | Compuestos de CBD fluorados, composiciones y usos de los mismos | |
| RU2013121788A (ru) | Ингибиторы репликации вич | |
| JP2022180461A5 (enExample) | ||
| JP2013509429A5 (enExample) | ||
| JP2013542247A5 (enExample) | ||
| JP2014506583A5 (enExample) | ||
| WO2013101897A3 (en) | Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid | |
| JP2011500781A5 (enExample) | ||
| JP2012530779A5 (enExample) | ||
| JP2015529229A5 (enExample) | ||
| EA201500293A1 (ru) | Антихолинэргическая нейропротективная композиция и способы | |
| RU2018135967A (ru) | Интраназальные фармацевтические композиции на основе бензодиазепина | |
| PE20091672A1 (es) | Nueva dosificacion y formulacion | |
| RU2015136849A (ru) | Композиции, содержащие 15-он эпк, и способы их применения | |
| NZ587202A (en) | Methods for measuring a patient response upon administration of a drug and compositions thereof | |
| BR112014029735A2 (pt) | forma de dosagem e formulação de abediterol | |
| JP2014515407A5 (enExample) | ||
| MD4369B1 (ro) | Utilizarea glicopirolatului pentru tratarea tahicardiei, doză unică, dispozitiv de administrare, metodă de tratament şi profilaxie a tahicardiei | |
| JP2015509075A5 (enExample) | ||
| AR087868A1 (es) | Compuestos de triazolopiridina como moduladores de la tirosina quinasa c-met | |
| RU2019110980A (ru) | Фармацевтические композиции, содержащие 15-гэпк, и способы лечения астмы и заболеваний легких с их применением | |
| RU2008124825A (ru) | Органические соединения, включающие соль гликопиррония | |
| JP2015502371A5 (enExample) |